Table 5.
Budget impact results in psoriasis, PsA and AS populations
| Psoriasis
| ||||
|---|---|---|---|---|
| Scenario without secukinumab
| ||||
| Cost type | 2017 | 2018 | 2019 | Cumulative |
| Drug acquisition costs | €160,598,891 | €160,238,525 | €160,532,731 | €481,370,147 |
| Administration costs | €1,073,573 | €1,891,112 | €1,913,789 | €4,878,474 |
| Adverse event-related costs | €1,573,845 | €1,300,406 | €1,244,296 | €4,118,547 |
| Disease-related costs | €13,273,866 | €13,353,509 | €13,433,630 | €40,061,006 |
|
| ||||
| Total | €176,520,175 | €176,783,553 | €177,124,446 | €530,428,174 |
|
| ||||
| Scenario with secukinumab | ||||
|
| ||||
| Drug acquisition costs | €159,038,303 | €157,823,581 | €157,388,333 | €474,250,217 |
| Administration costs | €914,293 | €1,544,311 | €1,654,992 | €4,113,595 |
| Adverse event-related costs | €1,387,727 | €1,182,537 | €1,173,404 | €3,743,667 |
| Disease-related costs | €13,273,866 | €13,353,509 | €13,433,630 | €40,061,006 |
|
| ||||
| Total | €174,614,189 | €173,903,939 | €173,650,358 | €522,168,486 |
|
| ||||
| Incremental budget impact (ΔTOTAL) | −€1,905,986 | −€2,879,614 | −€3,474,088 | −€8,259,688 |
| Incremental budget impact-percentage | −1% | −2% | −2% | −2% |
|
| ||||
| PsA | ||||
|
| ||||
| Scenario without secukinumab | ||||
|
| ||||
| Cost type | 2017 | 2018 | 2019 | Cumulative |
|
| ||||
| Drug acquisition costs | €143,587,227 | €142,366,020 | €140,297,479 | €426,250,726 |
| Administration costs | €1,546,523 | €1,893,814 | €1,916,392 | €5,356,730 |
| Adverse event-related costs | €835,171 | €843,274 | €848,486 | €2,526,931 |
| Disease-related costs | €20,047,089 | €20,167,372 | €20,288,376 | €60,502,837 |
|
| ||||
| Total | €166,016,011 | €165,270,480 | €163,350,732 | €494,637,223 |
|
| ||||
| Scenario with secukinumab | ||||
|
| ||||
| Drug acquisition costs | €139,575,949 | €135,570,840 | €132,204,159 | €407,350,947 |
| Administration costs | €1,403,927 | €1,658,146 | €1,763,156 | €4,825,228 |
| Adverse event-related costs | €852,602 | €872,383 | €884,689 | €2,609,673 |
| Disease-related costs | €20,047,089 | €20,167,372 | €20,288,376 | €60,502,837 |
|
| ||||
| Total | €161,879,566 | €158,268,740 | €155,140,379 | €475,288,686 |
|
| ||||
| Incremental budget impact (ΔTOTAL) | −€4,136,444 | −€7,001,740 | −€8,210,353 | −€19,348,538 |
| Incremental budget impact-percentage | −2% | −4% | `−5% | −4% |
|
| ||||
| AS | ||||
|
| ||||
| Scenario without secukinumab | ||||
|
| ||||
| Cost type | 2017 | 2018 | 2019 | Cumulative |
|
| ||||
| Drug acquisition costs | €96,048,990 | €95,067,510 | €94,127,419 | €285,243,919 |
| Administration costs | €1,722,661 | €1,724,020 | €2,194,834 | €5,641,515 |
| Adverse event-related costs | €269,268 | €256,987 | €263,424 | €789,679 |
| Disease-related costs | €9,348,044 | €9,404,132 | €9,460,557 | €28,212,732 |
|
| ||||
| Total | €107,388,963 | €106,452,649 | €106,046,234 | €319,887,846 |
|
| ||||
| Scenario with secukinumab | ||||
|
| ||||
| Drug acquisition costs | €87,812,247 | €81,930,766 | €77,814,015 | €247,557,028 |
| Administration costs | €1,506,887 | €1,468,436 | €1,836,154 | €4,811,478 |
| Adverse event-related costs | €273,623 | €268,165 | €276,185 | €817,974 |
| Disease-related costs | €9,348,044 | €9,404,132 | €9,460,557 | €28,212,732 |
|
| ||||
| Total | €98,940,802 | €93,071,499 | €89,386,911 | €281,399,212 |
|
| ||||
| Incremental budget impact (ΔTOT) | −€8,448,161 | −€13,381,149 | −€16,659,324 | −€38,488,634 |
| Incremental budget impact-percentage | −8% | −13% | −16% | −12% |
Abbreviations: AS, ankylosing spondylitis; PsA, psoriatic arthritis.